LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

A study reports that people living in lower income neighborhoods were at a higher risk for hidradenitis suppurativa.

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

The latest annual TIME100 Health list, which debuted in 2024, highlights scientists, doctors, advocates, educators, and other ...

Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the launch of the second edition Health Equity ...

Find insight on Riverstone Holdings, Bangkok Chain Hospital, Verano Holdings, and more in the latest Market Talks covering ...

In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment ...

Proxy advisor Ethos has called on Holcim shareholders to reject the company's remuneration proposals, saying Chairman Jan ...

These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...